Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Tilray Is Still a Very Risky Cannabis Stock

By Chris Lau, InvestorPlace Contributor

Many cannabis investors may want to pick Aurora or Cronos instead of TLRY stock, but Tilray could continue growing going forward.

Ford’s Bronco Launch is One of Many Positive Catalysts in Months Ahead

By Chris Lau, InvestorPlace Contributor

Once the economy picks up later this year and into next year, F stock is positioned to increase as Ford expands market share in both the gas-powered and EV markets.

American Airlines’ Goal Doesn’t Mean There’s More Value to the Stock

By Chris Lau, InvestorPlace Contributor

AAL stock rallied last week after forecasting a bold zero cash flow burn rate at the end of the year, a goal that may prove tough to reach.

Avoid Chasing Delta Airlines After Stock Price Took Off

By Chris Lau, InvestorPlace Contributor

Investors betting on Delta’s rebound already cashed in. Those who missed the rally should avoid chasing DAL stock.

Inovio Still a Hot Coronavirus Vaccine Supplier

By Chris Lau, InvestorPlace Contributor

INO stock is still attracting strong buying interest but investors may want to wait for the dust to settle first before adding shares.

Load More